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Background: Although sequential targeted therapy is standard in patients with metastatic clear-cell renal cell carcinoma
(m-ccRCC), the choice of drugs and optimal administration sequence have yet to be established. The objective of this
study was to explore whether it is preferable to rechallenge a long-term responder to a first-line tyrosine kinase inhibitor
(TKI) with a TKI or whether to switch to a mammalian target of rapamycin inhibitor (mTORi); to determine whether
second-line treatment response depends on duration of first-line response (TD1).
Patients and methods: Retrospective multicenter study (2004–2011) of 241 consecutive mRCC patients (clear-cell
histology) who received a first-line TKI for ≥6 months followed by a second-line TKI (n = 118) or mTORi (n = 123). End
points: Progression-free survival (PFS) and time-to-treatment failure (TTF) on second-line therapy. Multivariable full-model:
second-line drug, TD1, ECOG-PS before first- and second-line, best objective response (first-line), Fuhrman grade,
number of metastatic sites, and presence of bone metastases. Adjustment covariable: International mRCC Database
Consortium (IMDC) risk score. Multiple propensity score and missing data methods were used. Any correlation between
first-line and second-line PFS was investigated using censored quantile regression models (CQRM).
Results: Sequence effect in the overall cohort was in favor of the TKI–TKI sequence over the TKI–mTORi sequence on
using TD1 as continuous covariable (HR≈ 0.75 for PFS and TTF). TKI–TKI superiority was attributed in large part to the
11–22 month (TD1) subgroup of patients which displayed significantly better outcomes [HR≈ 0.5; median PFS (months):
9.4 (5.9–12.2) versus 3.9 (3.0–5.5), P = 0.003; TTF(months): 8.0 (5.5–11.0) versus 3.6 (3.0–4.6), P = 0.009]. Upon full
CQRM, long-term second-line responders were more likely to have received a second TKI than an mTORi and to have
been long-term responders to first-line TKI.
Conclusions: m-ccRCC patients who remained on first-line TKI between 11 and 22 months benefited from a TKI
rechallenge rather than from second-line mTORi.
Key words: kidney cancer, mammalian target of rapamycin (mTOR), sequence, tyrosine kinase inhibitor
introduction
Guidelines for the second-line treatment of patients with meta-
static clear-cell renal carcinoma (m-ccRCC) who have failed first-
line treatment with tyrosine kinase inhibitors (TKIs) targeting
vascular endothelial growth factor receptor (VEGFR) (sunitinib,
sorafenib, or pazopanib) recommend administration either of an
inhibitor of the mammalian target of rapamycin (mTORi), in
particular everolimus, or of the TKI axitinib [1, 2]. The evidence
underlying these guidelines, however, remains sparse [3–8].
Randomized trials have tested several drug sequences. The
RECORD-3 phase II trial comparing first-line everolimus fol-
lowed by second-line sunitinib versus the reverse sequence did
not demonstrate everolimus noninferiority versus sunitinib as
first-line but concluded in favor of the standard paradigm of
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sunitinib followed by everolimus [9]. In the AXIS phase III trial
comparing second-line axitinib to sorafenib, regardless of first-
line treatment, progression-free survival (PFS) but not overall
survival (OS) was better with axitinib [10]. On the other hand,
the INTORSECT phase III trial comparing second-line temsiro-
limus to sorafenib after TKI failure found no difference in
primary end point (PFS) but a benefit in secondary end point
(OS) for sorafenib [11].
A retrospective review conducted by the International
Metastatic Renal Cell Carcinoma Database Consortium (IMDC)
of 464 patients receiving different TKIs as first- and second-line
therapy detected no correlation between first- and second-line
PFS [12]. However, a recent subgroup analysis of the AXIS trial
showed that outcome to second-line therapy is better when
duration of first-line treatment is longer but underlined that, for
a given agent, prior response and length of therapy were not
convincing enough to help select second-line treatment [13].
A small retrospective study has suggested that long-term
responders to a first TKI who received a second-line TKI instead
of everolimus had better outcomes in terms of median PFS with
the second agent [14]. It has been suggested that the short- or
long-term response to a first-line TKI should guide optimal
choice of second-line agent [15].
None of the above studies focused specifically on long-term
responders. This in-depth retrospective analysis explores: (i)
whether it is preferable to rechallenge a long-term responder
with a TKI or whether to switch to an mTORi, (ii) whether dur-
ation of first-line response may help select second-line therapy.
patients andmethods
patient population
Data were retrospectively collected from the medical records of consecutive
m-ccRCC patients receiving sequential targeted therapy in 10 institutions in
4 European countries (2004–2011) after obtaining approval for the study
from the institutions’ ethics committees. At least 10 eligible patients per in-
stitution were needed for participation. Eligibility criteria were: clear-cell
histology and at least 6.0 months on first-line TKI followed by second-line
treatment with a TKI or an mTORi. Discontinuation of first-line treatment
due to toxicity was not a reason for exclusion as long as the ≥6 months eligi-
bility criterion was met. Exclusion criteria were unclear reasons for discon-
tinuing second-line therapy as well as treatment other than short-term
palliative procedures intervening between first- and second-line targeted
therapies. No semicurative cytoreductive surgery or stereotactic radiotherapy
was carried out during therapy. Immunotherapy before first-line TKI was
allowed.
data collected
We recorded demographics, histology, cancer history, sequential drugs use
with duration, best objective response upon Response Evaluation Criteria In
Solid Tumors (OR), reasons for first- and second-line discontinuation, and
data for calculating pretreatment prognostic scores [Memorial Sloan-Kettering
Cancer Center (MSKCC) and IMDC [16, 17]].
study end points
The main end point was PFS on second-line therapy with censoring of
patients who discontinued because of toxicity or for a therapeutic break,
regardless of any subsequent radiological disease progression. The secondary
end point was time-to-treatment failure (TTF) with censoring of patients
still undergoing treatment at last contact.
statistical analysis
Survival estimates were obtained by the Kaplan–Meier method. First-line
TKI treatment duration (TD1) was introduced as a continuous covariable.
Fixed TD1 intervals of either 6 or 11 months (i.e. 6–12, 12–18, 18–24, ≥24
months or 6–11, 11–22, ≥22 months, respectively) were also considered.
The relationship between sequence effect and time-to-event end points was
investigated using a Cox proportional-hazards regression model adjusting
for the following covariables: TD1, age at initial diagnosis, Fuhrman grade
score, number of metastatic sites, presence of bone metastases, OR on first-
line therapy, and ECOG-PS (Eastern Cooperative Oncology Group perform-
ance status) before first- and second-line therapy. We used a full-model ap-
proach (no prior variable selection) to avoid biased standard errors and
overoptimistic effects. Bias-corrected hazard ratios with confidence intervals
were obtained from 1000 bootstrap samples. We analyzed several datasets
for impact of missing data on outcomes: (i) complete-case analysis (deletion
of patients with ≥1 missing datum), (ii) full-information maximum likeli-
hood estimation, (iii) multiple imputation using fully conditional specifica-
tion, (iv) worst-case analysis with either TKI-worst or mTORi-worst.
We applied several methods: (i) to offset a possible between-sequence im-
balance in patient characteristics and account for reasons for first-line TKI dis-
continuation, we used propensity scores (PSc) with either Inverse Probability
of Treatment Weighting or Quintile Stratification, with IMDC risk score as an
adjustment covariable in addition to other covariables; (ii) to capture heteroge-
neous effects of second-line therapy and of TD1 on PFS and TTF distribution,
we used a full-model censored quantile regression based on Kaplan–Meier es-
timator of the cumulative hazard function to fit Log(PFS/TTF); (iii) to test for
delayed everolimus entry bias, we used a stratified log-rank test; (iv) to manage
short follow-ups, we conducted a sensitivity analysis for censoring. Details are
provided in the supplementary Material, available at Annals of Oncology
online. The P-value for statistical significance was 0.05. We used SASv9.3 (NY,
Cary) and Mplus6 (Muthén & Muthén) for full-information maximum
likelihood estimates.
results
patient characteristics
Overall, 313 patients who had received sequential targeted
therapy starting with a first-line TKI were screened for eligibility
[France (n = 222), Belgium (n = 49), Greece (n = 30), and Italy (n
= 12)]. Seventy-two patients were excluded (see Flowchart, sup-
plementary Figure S1, available at Annals of Oncology online).
The main reason (82%) was a TD1 <6 months (5.5–5.9 months).
Patients’ baseline characteristics and response to first-line TKI
are given in Table 1. Among 241 eligible patients, 206 (85%)
experienced progressive disease (PD) while on first-line TKI and
14 (6%) after discontinuation for toxicity or a break from therapy.
Overall, 35 patients (TKI–TKI = 19; TKI–mTORi = 16) discon-
tinued for reasons other than PD. A total of 118 patients received
second-line TKI whereas 123 patients received mTORi (some
received everolimus within the RECORD-1 trial or the REACT
expanded access program). Patient characteristics at initiation of
second-line therapy were well balanced (Table 1) with, however, a
higher proportion of poor-risk group patients receiving TKI–
mTORi. PD on second-line therapy occurred in 97 TKI–TKI and
96 TKI–mTORi patients (censoring rate 17.8% and 21.9%,
respectively); median follow-up was 35.1 [interquartile range
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Table 1. Patients’ characteristics at baseline and on initiation of second-line therapy, and outcomes on first-line therapy
All patients (n = 241) TKI–TKI (n = 118) TKI–mTORi (n = 123)
Baseline characteristics on first-line TKI therapy
Median age at diagnosis (IQR), years 58 (53–65) 56 (51–63) 59 (54–66)
Sex ratio (male/female) 2.8 2.9 2.7
Fuhrman grade, n (%)
1–2 52 (25) 27 (27) 25 (23)
3–4 156 (75) 74 (73) 82 (77)
Missing 33 17 16
Nephrectomized, n (%) 231 (96) 115 (97) 116 (94)
Missing 1 0 1
Number of metastatic sites, n (%)
1–2 160 (66) 81 (69) 79 (64)
>2 81 (34) 37 (31) 44 (36)
Presence of bone metastases, n (%) 56 (23) 25 (21) 31 (25)
ECOG-PS, n (%)
0 131 (59) 69 (63) 62 (54)
1–3 93 (41) 41 (37) 52 (46)
Missing 17 8 9
Risk group: MSKCC/IMDC, n (%)
Favorable 41 (21)/37 (18) 19 (20)/20 (20) 22 (22)/17 (16)
Intermediate 117 (60)/04 (52) 59 (63)/54 (56) 58 (57)/50 (49)
Poor 37 (19)/59 (30) 16 (17)/23 (24) 21 (21)/36 (35)
Missing 46/41 24/21 22/20
Median time since diagnosis (range), years 2.25 (0–27.5) 2.9 (0–24.8) 1.9 (0–27.5)
First-line TKI, n (%)
Sunitinib 202 (83) 93 (78) 109 (89)
Sorafenib 37 (15) 25 (21) 12 (10)
Pazopanib 2 (0.8) 0 2 (1.6)
Outcomes on first-line TKI therapy
Best response, n (%)
Complete response 1 (0.4) 0 1 (0.8)
Partial response 99 (42) 42 (37) 57 (48)
Stable disease 133 (57) 73 (63) 60 (51)
Missing 8 3 5
Reason for discontinuing TKI, n (%)
Progressive disease 206 (85) 99 (84) 107 (87)
Toxicity 20 (8.3) 9 (7.6) 11 (8.9)
Other (break/surgery/radiotherapy) 15 (6) 10 (8) 5 (4)
Median TD1 (95% CI), months 14.6 (12.8–17.2) 14.7 (12.1–17.5) 14.2 (12.4–18.8)
TD1 stratification, n (%)
6–11 months 80 (33) 39 (33) 41 (33)
>11–22 months 93 (39) 51 (43) 42 (34)
>22 months 68 (28) 28 (24) 40 (32)
Characteristics on initiation of second-line therapy
ECOG-PS, n (%)
0 75 (34) 38 (37) 37 (32)
1–3 143 (66) 65 (63) 78 (68)
Missing 23 15 8
Risk group: MSKCC/IMDC, n (%)
Favorable 11 (6)/10 (5) 6 (7)/6 (6) 5 (5)/4 (4)
Intermediate 123 (64)/121 (60) 65 (74)/63 (67) 58 (56)/58 (54)
Poor 57 (30)/71 (35) 17 (19)/25 (27) 40 (39)/46 (43)
Missing 62/39 34/24 28/15
Second-line treatment, n (%)
Sunitinib 32 (13) 32 (27) –
Sorafenib 82 (34) 82 (69) –
Pazopanib 1 (0.4) 1 (0.8) –
Continued
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(IQR): 20.8–70.9] and 22.9 (IQR: 13.4–30.6) months, respectively;
7 (5.9%) and 13 (10.5%) patients on second-line therapy were
censored for TTF [median follow-up, 20.3 (IQR: 11.7–35.1) and
9.6 (IQR: 5.5–22.9) months, respectively].
second-line outcomes
When using TD1 as a continuous covariable for the whole
cohort, the sequence effect was in favor of the TKI–TKI se-
quence over the TKI–mTORi sequence, regardless of dataset.
The HR averaged over all datasets was 0.75 for both PFS
(Figure 1A) and TTF (supplementary Figure S2A, available at
Annals of Oncology online). The estimated benefit afforded by
the TKI–TKI sequence was, however, mainly due to the 11–22
month TD1 subgroup in all datasets (Figure 1C, supplementary
Figure S2C, available at Annals of Oncology online). The aver-
aged HR in this subgroup was 0.5 for PFS and 0.65 for TTF,
with significantly better outcomes for the TKI–TKI than TKI–
mTORi sequence [complete-case dataset PFS: 9.4 (5.9–12.2)
versus 3.9 (3.0–5.5) months, unadjusted P = 0.003; TTF: 8.0
(5.5–11.0) versus 3.6 (3.0–4.6) months, unadjusted P = 0.009]
(supplementary Figure S3A and B, available at Annals of
Oncology online). The averaged between-sequence difference in
median PFS and TTF was 5.5 months (supplementary Table S1,
available at Annals of Oncology online). Neither sequence predo-
minated in the 6–11 month or >22 month subgroups (Figure 1B
and D, supplementary Figure S2B and D, available at Annals of
Oncology online). Similar results were obtained on exclusion of
the 35 patients who discontinued for reasons other than PD.
substantiation of TKI–TKI sequence superiority
In a subgroup analysis of the full-model with no PSc, a significant
interaction between second-line therapy and the 11–22 month
TD1 subgroup was observed for PFS (but not TTF) for most data-
sets, supporting TKI–TKI superiority in this subgroup (Figure 2,
supplementary Table S2, available at Annals of Oncology online).
The 12–18 and 18–24 month TD1 subgroups also emphasized
an advantage of the TKI–TKI sequence but lacked the power
needed to reach statistical significance. Despite no PSc, there was
no significant interaction between IMDC risk group and second-
line therapy, thus excluding bias from between-sequence imbal-
ance in risk before second-line therapy.
variable effects of second-line drug class and TD1
on second-line end points
The effect of the second-line drug and of TD1 might vary
according to the PFS and/or TTF distribution on second-line
therapy. We investigated linear models fitted to 25th (short-
term), 50th (median-term), and 75th (long-term) PFS or TTF
percentiles (PFS: 2.8, 5.5, and 13.3 months; TTF: 2.5, 4.9, and
11.2, respectively) over all datasets. The TKI–TKI sequence pro-
vided a 1.2–1.8 month gain in PFS and in TTF regardless of
whether the patient was a short, median, or long-term second-
line responder (Figure 3A, supplementary Figure S4A, available
at Annals of Oncology online). The second-line drug effect was
statistically significant in long-term responders for the com-
plete-case and worst-case (TKI-worst) datasets, with or without
PSc, for both PFS and TTF. The impact of TD1 on PFS was par-
ticularly clinically significant for PFS in the long-term second-
line responders, with a 3-month gain per each additional 6
months on first-line therapy, compared with a 1.0–1.5 month
gain in short- and median-term responders (Figure 3B, supple-
mentary Figure S4B, available at Annals of Oncology online). In
short, long-term second-line responders were more likely to
have received a second TKI and to have been long-term respon-
ders to first-line TKI.
discussion
According to our analysis, patients who received a first-line TKI
for at least 6 months benefited more from TKI rechallenge than
from a switch to an mTORi. However, this observation applied
primarily to the patient subgroup on first-line TKI between 11
and 22 months. The sequence effect was consistent across a
series of datasets. Although the better tolerance of mTORi over
TKI may have led to mTORi being reserved for less fit and TKI
for fitter patients, we found that risk group did not impinge on
sequence effect in patients with long-term responses.
Our findings are consistent with those of several earlier retro-
spective studies: (i) in a comparison of TKI–TKI–everolimus
versus TKI–everolimus–TKI (n = 19 versus 14), only patients
with a >9-month first-line TKI response experienced a 7.5-
month gain in second-line PFS (P = 0.02) [14]; (ii) in a compari-
son of VEGF-targeted versus mTORi therapy after first-line
VEGF-targeted therapy (n = 192 versus 24), VEGF-targeted
therapy yielded a 2.3-month gain in TTF (P = 0.014) [18].
Table 1. Continued
All patients (n = 241) TKI–TKI (n = 118) TKI–mTORi (n = 123)
Axitinib 3 (1.2) 3 (2.5) –
Everolimus 109 (45) – 109 (89)
Temsirolimus 14 (6) – 14 (11)
Percentages are rounded to nearest integer and given as percentages of nonmissing values. Correlation between ECOG-PS and Karnofsky PS (when
available): χ2, P < 0.0001.
IQR, interquartile range; TKI, tyrosine kinase inhibitor; mTORi, mTOR inhibitor; ECOG-PS, Eastern Cooperative Oncology Group performance
status; TD1, first-line treatment duration; TTF1, time-to-treatment failure on first-line therapy; CI, confidence interval; MSKCC, Memorial Sloan-
Kettering Cancer Center risk group; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium risk group.
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When adjusted on first-line therapy, the TTF difference favored
rechallenge (HR = 0.481, P = 0.016); (iii) in a comparison of
sunitinib–sorafenib–everolimus versus sunitinib–everolimus–
sorafenib (n = 71 versus 56), the former sequence provided a
significant PFS gain [PFS: 11.2 and 7.7 months for sunitinib
(28% patients) and sorafenib (33%), respectively, and 4.8 and
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Figure 1. Sequence effect (hazard ratio with 95% CI) for second-line progression-free survival (per dataset, with or without propensity score): (A) TD1 as con-
tinuous covariable, (B) TD1: 6–11 months, (C) TD1: 11–22 months, (D) TD1: >22 months (TD1: first-line TKI treatment duration). CI: confidence interval;
TD1, first-line treatment duration.
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3.6 months for everolimus (28%) and temsirolimus (10%),
respectively, P = 0.006] [19]. Our median PFS values of 7.3 and
5.2 months for second-line TKI and mTORi, respectively,
support these results.
Some studies have detected no difference between second-line
targeted therapies. A study of second-line TKI and mTORi
(n = 41 versus 42) in first-line TKI failures found both treat-
ments to be as effective in terms of PFS and OS [20]. Everolimus
showed no clear benefit in a comparison of VEGFi–TKI–
mTORi versus VEGFi–mTORi–TKI (n = 62 versus 41) [21] al-
though it improved OS, but not PFS, in a comparison of
VEGFi–TKI versus VEGFi–mTORi (n = 46 versus 62) by the
same team [22]. In the INTORSECT trial, there was no signifi-
cant difference in median PFS between sorafenib and temsiroli-
mus (HR = 0.87, P = 0.19) although sorafenib improved OS [11].
Our findings differ from those of two large-scale retrospective
reviews in favor of the TKI–mTORi sequence: (i) In a study of
257 sunitinib-treated patients, risk of second-line treatment
failure was significantly higher with temsirolimus and with sora-
fenib than with everolimus [23]; (ii) in a medical record review
of second-line everolimus, temsirolimus, and sorafenib after a
TKI (n = 233, 178, and 123, respectively), everolimus was asso-
ciated with numerically prolonged PFS compared with sorafenib
[24]. It should be stressed, however, that temsirolimus, unlike
everolimus, is usually reserved for poor prognosis patients.
Moreover, these reviews overlooked first-line TKI response.
Only the AXIS trial subgroup analysis has considered first-line
TKI response (9.7-month cut-off ) when evaluating the benefit
of a second-line TKI [13].
To our knowledge, previous line treatment duration is rarely
used as a covariable when modeling subsequent lines. In our
study, sequence effect depended on the side of the second-line
response distribution being modeled. The TD1 effect was more
stringent in long- rather than short-term second-line responders.
Characterization of a posteriori long-term responders in studies
involving a third line might help substantiate this observation.
The mechanisms underlying our results require elucidation.
If VEGF/VEGFR-driven angiogenesis remains a key feature of
advanced disease and a TKI has a more direct antiangiogenic
action than an mTORi, then TKI superiority over mTORi may
not be that surprising. An antiangiogenic effect might be the
primary mechanism of action of mTORi in mTORi-treated
m-ccRCC patients, other than those with ‘metabolic’ RCCs har-
boring mTOR gene mutations [25]. After failure of a first TKI,
continued kinase suppression of persisting TKI-sensitive clones
might slow down disease progression [26]. On the other hand,
the 6–11-month TD1 subgroup might have developed resistance
to TKI or had faster growing tumors [27] whereas the >22-
month TD1 subgroup might have had more indolent disease
less sensitive to drug type. Why TTF, unlike PFS, did not reach
statistical significance in the subgroup analysis in all datasets
remains, however, unclear.
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Figure 2. Subgroup analysis of sequence effect (progression-free survival as end point, full-information maximum likelihood dataset, no propensity score).
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The methodological strengths of our study are: (i) a homoge-
neous multicentric cohort of m-ccRCC patients receiving a first-
line TKI for ≥6 months; (ii) well-balanced treatment groups;
(iii) compensation for loss in statistical power from exclusion of
patients with missing data in the complete-case dataset by
analysis of four extra datasets (the similarity in results across
datasets confirmed that missing data did not impact on overall
sequence effect and that the missing completely at random as-
sumption was reasonable); (iv) adjustment by PSc for any bias
due to between-sequence imbalance in risk before second-line
treatment. In any case, risk group had no impact on the relation-
ship between sequence and outcome (PFS or TTF). The benefit
of a second-line TKI remained significant even on worst-case
analysis favoring the TKI–mTORi sequence (virtually restoring
balance in poor prognosis patients who tended to receive
mTORi more often). Moreover, the interaction term between
risk group and sequence was not significant.
Our study has limitations: (i) a retrospective design but
one that reflects real-life clinical practice in long-term respon-
ders across Europe; (ii) differences in radiological assessment
schedules that might have led to the benefit of a particular
sequence being slightly overestimated; (iii) a relatively short
follow-up period in 14 TKI–mTORi patients at the time of
data analysis although short follow-up did not influence reli-
ability of estimates in a sensitivity analysis; (iv) lack of infor-
mation on cytokine pretreatment and dose reductions; (v)
inability to relate OS to sequence because of subsequent ther-
apies; (vi) an emphasis on second-line sorafenib rather than
axitinib which had not yet been approved when the patients
were being treated.
conclusion
Given the limited number of drug classes available to treat
patients with m-ccRCC, physicians inevitably face the decision
whether to reintroduce a drug belonging to an earlier therapeut-
ic class that yielded a clinically significant response or to switch
to another class of drug. Our findings suggest that a second-line
TKI might be a pragmatic and beneficial option in long-term
responders to a first-line TKI (between 11 and 22 months) in
whom drug toxicity is manageable. This would now require
confirmation in a prospective trial.
4.0 A
B
3.5
3.0
2.5
2.0
1.5
1.0
0.5
Ad
di
tio
na
l P
FS
 (m
on
ths
)
4.0
3.5
2.5
2.0
1.5
1.0
0.5
0.8
0.4
0.5
0.4
0.5
0.3
0.01 0.02
0.2 0.2 0.2 0.2
0.01
0.1 0.2
0.3
0.4
0.004
0.4 0.5 0.5
0.2 0.3
0.70.80.7
0.03
0.03
0.050.06
0.3
0.5 0.6
0.8
Short
No propensity score
Quantile stratification
Inverse probability treatment weight
Median
Second-line responders
Long
0.8 >0.9
3.0
Figure 3. Gain in progression-free survival in short, median, and long-term second-line responders: (A) On administering a TKI versus an mTORi; (B) for
each additional 6 months in TD1. Extreme P-values of the effect estimate in the different datasets are shown above and below the high–low plots.
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